We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+12.64%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$393M
AUM Growth
+$191M
(+94%)
Cap. Flow
+$74.6M
Cap. Flow
% of AUM
18.98%
Top 10 Holdings %
Top 10 Hldgs %
69.35%
Holding
62
New
18
Increased
13
Reduced
5
Closed
15
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.7
quarters
Top 20 Avg Time Held Equity + Options
1.7
quarters
Avg Time Held Equity only
3.4
quarters
Top 10 Avg Time Held Equity only
2.7
quarters
Top 20 Avg Time Held Equity only
1.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$32.2M |
| 2 |
Labcorp
LH
|
+$32M |
| 3 |
GSK
GSK
|
+$17.2M |
| 4 |
Globus Medical
GMED
|
+$8.27M |
| 5 |
Patterson Companies, Inc.
PDCO
|
+$6.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$27.4M |
| 2 |
Cencora
COR
|
+$20.5M |
| 3 |
Medtronic
MDT
|
+$6.77M |
| 4 |
Avantor
AVTR
|
+$5.99M |
| 5 |
Relay Therapeutics
RLAY
|
+$3.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.9% |
| 2 | Miscellaneous | 28.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
GE HealthCare
GEHC
$31.1B
| $48.7M | 12.39% |
599,808
+402,921
| +205% | +$32.2M |
2023 Q1
1 quarter
|
|
2
PUT
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $44.1M | 11.21% |
+154,400
| New | +$42.9M |
2023 Q2
0 quarters
|
|
|
3
Labcorp
LH
$25.4B
| $34.2M | 8.71% |
+165,179
| New | +$32M |
2023 Q2
0 quarters
|
|
4
Cigna
CI
$74.7B
| $31.6M | 8.04% |
112,674
+25,499
| +29% | +$6.64M |
2020 Q3
11 quarters
|
|
5
Bicycle Therapeutics
BCYC
$254M
| $24.7M | 6.29% |
968,671
+1,324
| +0.1% | +$30.8K |
2021 Q4
6 quarters
|
|
6
PUT
Stryker
SYK
$108B
| $24.4M | 6.21% |
+80,000
| New | +$23.1M |
2023 Q2
0 quarters
|
|
7
United Therapeutics
UTHR
$23.3B
| $17.6M | 4.49% |
79,926
+4,923
| +7% | +$1.09M |
2018 Q4
18 quarters
|
|
8
PUT
Medifast
MED
$130M
| $17.5M | 4.45% |
+190,000
| New | +$16.9M |
2023 Q2
0 quarters
|
|
|
9
GSK
GSK
$92.7B
| $17.1M | 4.35% |
+479,532
| New | +$17.2M |
2023 Q2
0 quarters
|
|
|
10
Globus Medical
GMED
$10.2B
| $12.7M | 3.22% |
212,593
+145,093
| +215% | +$8.27M |
2023 Q1
1 quarter
|
|
11
PUT
Align Technology
ALGN
$10.2B
| $12.2M | 3.1% |
+34,500
| New | +$11M |
2023 Q2
0 quarters
|
|
12
PUT
Intuitive Surgical
ISRG
$149B
| $12.1M | 3.09% |
+35,500
| New | +$10.7M |
2023 Q2
0 quarters
|
|
13
ADC Therapeutics
ADCT
$217M
| $8.64M | 2.2% |
4,020,705
+1,860,073
| +86% | +$4.18M |
2023 Q1
1 quarter
|
|
14
Viking Therapeutics
VKTX
$3.39B
| $8.55M | 2.18% |
527,657
+277,657
| +111% | +$5.82M |
2023 Q1
1 quarter
|
|
15
Organon & Co
OGN
$3.62B
| $8.43M | 2.14% |
404,938
-66,615
| -14% | -$1.45M |
2022 Q2
4 quarters
|
|
16
DELISTED
Axonics, Inc. Common Stock
AXNX
| $8.28M | 2.11% |
164,017
+93,176
| +132% | +$4.96M |
2023 Q1
1 quarter
|
|
|
17
DELISTED
Patterson Companies, Inc.
PDCO
| $8.15M | 2.07% |
+245,000
| New | +$6.75M |
2023 Q2
0 quarters
|
|
18
Humana
HUM
$50.5B
| $5.81M | 1.48% |
+13,000
| New | +$6.54M |
2023 Q2
0 quarters
|
|
|
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
| $5.43M | 1.38% |
877,193
+529,324
| +152% | +$2.51M |
2023 Q1
1 quarter
|
|
20
DELISTED
Immunogen Inc
IMGN
| $4.64M | 1.18% |
+245,921
| New | +$2.9M |
2023 Q2
0 quarters
|
|
21
Nektar Therapeutics
NKTR
$1.29B
| $4.02M | 1.02% |
+466,359
| New | +$4.97M |
2023 Q2
0 quarters
|
|
22
ARS Pharmaceuticals
SPRY
$403M
| $3.64M | 0.92% |
+542,576
| New | +$3.62M |
2023 Q2
0 quarters
|
|
23
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.58M | 0.91% |
+141,500
| New | +$4.41M |
2023 Q2
0 quarters
|
|
24
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $3.58M | 0.91% |
290,749
+17,906
| +7% | +$224K |
2022 Q4
2 quarters
|
|
25
X4 Pharmaceuticals
XFOR
$258M
| $3.39M | 0.86% |
+58,300
| New | +$3M |
2023 Q2
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Sio Capital Management held 62 positions worth $393M, up 94% from $202M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Sio Capital Management deployed $74.6M of net new capital in Q2 2023, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was Labcorp: 165,179 shares worth $34.2M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Repare Therapeutics, an estimated $1.57M trimmed.
- Sio Capital Management's largest Q2 2023 buy was Labcorp: 165,179 shares worth $34.2M.
- Sio Capital Management added most to GE HealthCare in Q2 2023, an estimated $32.2M increase.
- Sio Capital Management's biggest Q2 2023 reduction was Repare Therapeutics, cutting an estimated $1.57M.
- Sio Capital Management fully exited Centene in Q2 2023, selling an estimated $27.4M.
- Sio Capital Management's ten largest holdings make up 69% of its $393M portfolio in Q2 2023.
- Sio Capital Management opened 18 new positions and closed 15 in Q2 2023.
- Sio Capital Management's portfolio value rose 94% quarter-over-quarter to $393M.
Based on Sio Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.